Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-17
2011-12-27
Kemmerer, Elizabeth C (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S001900, C514S016400, C514S021500, C530S300000, C530S327000, C530S402000
Reexamination Certificate
active
08084423
ABSTRACT:
The present invention is directed to a synthetic apolipoprotein-E mimicking polypeptide consisting of a single domain. The invention is also directed to nucleic acid encoding the polypeptide, vectors including the nucleic acid, antibodies specific for the polypeptide, and compositions comprising the same and methods of using the same.
REFERENCES:
patent: 4877611 (1989-10-01), Cantrell
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5579250 (1996-11-01), Balaji et al.
patent: 5612895 (1997-03-01), Balaji et al.
patent: 5631280 (1997-05-01), Ciccarone et al.
patent: 5843708 (1998-12-01), Hardman et al.
patent: 5877153 (1999-03-01), Harris et al.
patent: 6107457 (2000-08-01), Arlinghaus et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 6201165 (2001-03-01), Grant et al.
patent: 6423511 (2002-07-01), Nakamura et al.
patent: 6444111 (2002-09-01), Montgomery
patent: 6458592 (2002-10-01), Jakobovitz et al.
patent: 6472184 (2002-10-01), Hegemann
patent: 6514523 (2003-02-01), Sparks
patent: 6664230 (2003-12-01), Fogelman et al.
patent: 6930085 (2005-08-01), Fogelman et al.
patent: 6933279 (2005-08-01), Fogelman et al.
patent: 7144862 (2006-12-01), Fogelman et al.
patent: 7166578 (2007-01-01), Fogelman et al.
patent: 7199102 (2007-04-01), Fogelman et al.
patent: 7563771 (2009-07-01), Anantharamiah et al.
patent: 7579319 (2009-08-01), Fogelman et al.
patent: 2004/0186057 (2004-09-01), Anantharamiah et al.
patent: 2005/0164950 (2005-07-01), Fogelman et al.
patent: 2007/0032430 (2007-02-01), Fogelman et al.
patent: 2007/0254839 (2007-11-01), Fogelman et al.
patent: WO86/01533 (1986-03-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 02/15923 (2002-02-01), None
patent: WO 03/086326 (2003-10-01), None
Weers et al., Eur., J., Biochem., 2001, vol. 268: 3728-3735.
Zaiou et al., J. Lipid Res., 2000, vol. 41:1087-1095.
Qin et al., Circulation, 2006, vol. 114:II-110.
Eck, S. L. and Wilson, J. M.,1996, in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York.
Abrahmsen, et al.Biochemistry30: 4151 (1991).
Alvarez and Curiel,Hum. Gene Ther., 8:597-613 (1997).
Baggiolini, et al.FEBS Lett. 307: 97-101 (1992).
Beisiegel, et al.Nature341: 162-164 (1989).
Brigham, et al.Am. J. Resp. Cell. Mol. Biol. 1:95-100 (1989).
Catapano, et al.J. Biol. Chem. 254: 1007-1009 (1979).
Clark-Lewis, et al.Biochemistry30: 3128 (1991).
Crystal,Hum. Gene Ther., 8: 985-1001 (1997).
Datta, et al.Biochemistry30: 213-220 (2000).
Datta, et al.,Journal of Lipid Research42: 959-966 (2001).
Dashti, et al.Journal of Lipid Res. 45: 1919-1928 (2004).
Dawson, et al.Science266: 776-779 (1994).
Deedwania, P.C.Med. Clin. North Am. 79: 973-998 (1995).
Eisenberg, et al.J. Chin Invest. 90: 2013-2021 (1992).
Felgner, et al.PNAS, 84: 7413-7417 (1987).
Garber, et al.J. Lipid. Res. 41: 1020-1026 (2000).
Gianturco, et al.,Journal of Lipid Research23: 984-993 (1982).
Havel, R. J.Arteriosclerosis5: 569-580 (1985).
Hussain, et al.J. Biol. Chem. 275: 29324-29330 (2000).
Illingworth, et al.Current Opini. Lipidol. 10: 383-386 (1999).
Johnson,Posttranslational Covalent Modification of Proteins, Ed.,Academic Press, New York, pp. 1-17 (1983).
Jones, et al. “Computer programs to identify and classify amphipathic of domains.”J. Lipid. Res. 33: 287-296 (1992).
Kwiterovich, and GuytonAm. J. Cardiol. 82: U-7U (1998).
Linton and Fazio,Curr. Opin. Lipidol. 10: 97-105 (1999).
Mahley, et al.J. Lipid Res. 40: 622-630 (1999).
Marais, .Curr. Opin. Lipidol. 11: 597-602 (2000).
Miller, et al.Mol. Cell. Biol. 6: 2895 (1986).
Paka, et al.J. Biol. Chem. 274: 4816-4823 (1999).
Pastan, et al.PNAS, 85: 4486 (1988).
Rajarathnam, et al.Biochemistry33: 6623-6630 (1994).
Ramprasad, et al.J. Controlled Release, 79: 207-218 (2002).
Schnolzer, et al.Science256: 221 (1992).
Schonfeld, et al.J. Clin. Invest. 64: 1288-1297 (1979).
Segrest, et al.Proteins: Structure, Function and Genetics, 8: 103-117 (1990).
Segrest, et al.Structure of the plasma lipoproteins in “Atlas of Atherosclerosis” 2nded., edited by P.W.F. Wilson, p. 56 (2000).
Spira, et al.J. Immun. Methods7: 307 (1984).
Steplewski, et al.PNAS82: 8653 (1985).
Swarnakar, et al.J. Biol. Chem. 276: 21121-21126 (2001).
Tytler, et al.J. Biol. Chem. 268: 2212-2218 (1993).
Watts, et al.Atherosclerosis141: 17-30 (1998).
Wigland et al.In: Adenovirus DNA, Martinus Nijhoff Publishing, Boston, 408-441 (1986).
Wilson et al.Science252: 1817-1822 (1991).
Zaiou et al.,Journal of Lipid Research41: 1087-1095 (2000).
Datta G, White CR, Dashti N, Chaddha M, Palgunachari MN, Gupta H, Handattu SP, Garber DW, Anantharamaiah GM. (2009) Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis Epub ahead of print. Volume and page TBA.
Garber DW, Handattu S, Aslan I, Datta G, Chaddha M, Anantharamaiah GM. (2003) Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 168(2):229-237.
Anantharamaiah G, Navab M, Reddy ST, Garber DW, Datta G, Gupta H, White CR, Handattu SP, Palgunachari MN, Chaddha M, Mishra VK, Segrest JP, Fogelman AM. (2006) Synthetic peptides: managing lipid disorders. Curr Opin Lipidol. 17(3): 233-237.
Anantharamaiah GM, Mishra VK, Garber DW, Datta G, Handattu SP, Palgunachari MN, Chaddha M, Navab M, Reddy ST, Segrest JP, Fogelman AM. (2007) Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res. 48(9): 1915-1923.
Bechinger B. (2000) Understanding peptide interactions with the lipid bilayer: a guide to membrane protein engineering. Curr Opin Chem Biol. 4(6):639-644.
Blackburn WD Jr, Dohlman JG, Venkatachalapathi YV, Pillion DJ, Koopman WJ, Segrest JP, Anantharamaiah GM. (1991) Apolipoprotein A-I decreases neutrophil degranulation and superoxide production. J Lipid Res. 32(12): 1911-1918.
Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, Wagner AC, Fogelman AM, Brahn E. (2008) Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol. 127(2): 234-244.
Clark-Lewis I, Dewald B, Loetscher M, Moser B, Baggiolini M. (1994) Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem. 269(23): 16075-16081.
Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM. (1994) HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb. 14(11): 1775-1783.
Geysen HM, Mason TJ, Rodda SJ. (1988) Cognitive features of continuous antigenic determinants. J Mol Recognit. 1(1): 32-41.
Gupta H, Dai L, Datta G, Garber DW, Grenett H, Li Y, Mishra V, Palgunachari MN, Handattu S, Gianturco SH, Bradley WA, Anantharamaiah GM, White CR. (2005) Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res. 97(3): 236-243.
Gupta H, White CR, Handattu S, Garber DW, Datta G, Chaddha M, Dai L, Gianturco SH, Bradley WA, Anantharamaiah GM. (2005) Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation. 111(23): 3112-3118.
Kandel ER, Schwartz JH, Jessell TM (Eds.) (1991) Principles of Neural Science, Third Edition. Elsevier: New York, pp. 188-189.
Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. (2002) Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105(3): 290-292.
Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP. (1990) Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest. 86(4): 1142-1150.
Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary
Anantharamiah Gattadahalli M.
Datta Geeta
Garber David W.
Ballard Spahr LLP
Kemmerer Elizabeth C
UAB Research Foundation
Xie Xiaozhen
LandOfFree
Synthetic single domain polypeptides mimicking... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic single domain polypeptides mimicking..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic single domain polypeptides mimicking... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313291